** Drug developer Eton Pharmaceuticals' ETON.O shares rise 6.2% to $15.51 premarket
** Company says its experimental drug, ET-600, passed a bioequivalence study against an FDA-approved reference product with the same active ingredient for treatment of a rare condition called central diabetes insipidus $(CDI.NZ)$
** A bioequivalence study compares a generic test formulation with the original reference drug
** CDI is an uncommon problem in which the body can't properly balance fluid levels prompting to make large amounts of urine
** Eton Pharma plans to file FDA marketing application in April 2025
** As of last close, company's shares have more than tripled in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.